Talk turned to the finer points of phase IIb data from the trial called ROYAL-1 – in particular, success with regard to high-sensitivity C-reactive protein (hsCRP) – after Wall Street put a dent in Gemphire Therapeutics Inc., despite the fact that gemcabene achieved its primary endpoint of cholesterol lowering in the study.